CVTX - CV Therapeutics, Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CVTX - CV Therapeutics, Inc.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Todd N. Weisrock who started this subject	1/22/2004 6:36:01 PM
From: Doc Bones	Read Replies (1) of 411

17:39 Business Week comments on CVTX According to BusinessWeek, CV Therapeutics (CVTX ) has been bouncing around on rumors of what the FDA might do about Ranexa. The stock dropped from $18 in Nov to $12 on Dec. 8, when an FDA panel sought more data on the drug causing concerns among analysts. But as of Jan 21 the stock had risen back up to $15.17 which may be due to the Jan. 21 issue of the Journal of the American Medical Assn., which said Ranexa significantly reduced angina frequency. Some investors now say it may get early FDA approval and although CVTX has yet to make any money the approval of Ranexa could be a major coup for co. With the stock's low price and better prospects, CVTX could be buyout bait for big drugmakers who are purchasing biotechs to fill their pipeline (In late 2000, as takeover talk swirled, CVTX soared to $80). [briefing]

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next